Holen Sie sich die Stockscreener-App
2.24
18.52%
0.35
Schlusskurs vom Vortag:
$1.89
Offen:
$1.91
24-Stunden-Volumen:
6.86M
Relative Volume:
1.71
Marktkapitalisierung:
$347.47M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-110.78M
KGV:
-2.0935
EPS:
-1.07
Netto-Cashflow:
$-75.59M
1W Leistung:
+88.24%
1M Leistung:
+44.52%
6M Leistung:
-53.67%
1J Leistung:
-65.11%
1-Tages-Spanne:
$1.7903
$2.26
1-Wochen-Bereich:
$1.21
$2.26
52-Wochen-Spanne:
$1.15
$9.97
Humacyte Inc Stock (HUMA) Company Profile
Firmenname
Humacyte Inc
Sektor
Branche
Telefon
919-313-9633
Adresse
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Vergleichen Sie HUMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
2.24 | 184.59M | 0 | -110.78M | -75.59M | -1.07 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2023-12-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-14 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-16 | Herabstufung | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | Eingeleitet | Cowen | Outperform |
| 2021-09-24 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-22 | Eingeleitet | BTIG Research | Buy |
| 2021-09-16 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Humacyte Inc Aktie (HUMA) Neueste Nachrichten
Humacyte’s Earnings Call Highlights Success and Challenges - TipRanks
Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates - MSN
Humacyte (HUMA) Receives Buy Rating and $4.00 Price Target from HC Wainwright & Co. | HUMA Stock News - GuruFocus
Humacyte (HUMA) Gains Buy Rating with $4 Target | HUMA Stock New - GuruFocus
Benchmark cuts Humacyte stock target to $14, maintains Buy rating By Investing.com - Investing.com South Africa
Humacyte (HUMA) Reports Lower-Than-Expected Q1 Revenue Amid Symv - GuruFocus
Humacyte, Inc.: Spare Parts for People - Outsider Club
Humacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026 - MSN
Benchmark cuts Humacyte stock target to $14, maintains Buy rating - Investing.com
Humacyte (HUMA) Price Target Reduced by Benchmark Amid Positive Outlook | HUMA Stock News - GuruFocus
Humacyte (HUMA) Focuses on Symvess Launch and Expansion Plans - GuruFocus
Humacyte, Inc. (NASDAQ:HUMA) Q1 2025 Earnings Call Transcript - Insider Monkey
Humacyte price target lowered to $14 from $17 at Benchmark - TipRanks
Durham firm with battered stock cuts jobs to save cash - The Business Journals
Humacyte Reports Q1 2025 Earnings and Strategic Progress - TipRanks
Earnings call transcript: Humacyte Q1 2025 beats EPS forecast, stock surges - Investing.com Nigeria
Humacyte, Inc. SEC 10-Q Report - TradingView
Positive Momentum and Financial Stability Drive Buy Recommendation for Humacyte - TipRanks
Humacyte (HUMA) Receives Continued 'Buy' Rating from Analyst | - GuruFocus
Transcript : Humacyte, Inc., Q1 2025 Earnings Call, May 13, 2025 - marketscreener.com
Humacyte (HUMA) Anticipates Q1 Earnings Announcement - GuruFocus
Humacyte, Inc. Reports First Quarter 2025 Financial Results and Market Launch of Symvess™ for Vascular Trauma Treatment - Nasdaq
Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update - TradingView
Humacyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Humacyte Q1 2025 Earnings Call Transcript - MarketBeat
Levi & Korsinsky Notifies Shareholders of Humacyte, Inc. (HUMA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Shareholders - ACCESS Newswire
HUMA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
HUMA Shareholders Have Opportunity to Lead Humacyte, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Class Action Filed Against Humacyte, Inc. (HUMA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. LawsuitHUMA - ACCESS Newswire
HUMA LAWSUIT ALERT: Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Investors in Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - ACCESS Newswire
Humacyte, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationHUMA - ACCESS Newswire
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc.(HUMA) Shareholders - ACCESS Newswire
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025 - The Manila Times
Humacyte, Inc. to Release First Quarter 2025 Financial Results on May 13, 2025 - Nasdaq
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA ViolationsHagens Berman - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Humacyte, Inc.(HUMA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Humacyte, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationHUMA - ACCESS Newswire
Shareholders that lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class ActionHUMA - ACCESS Newswire
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know - MSN
Humacyte Insiders Placed Bullish Bets Worth US$949.4k - Yahoo Finance
All You Need to Know About Humacyte, Inc. (HUMA) Rating Upgrade to Buy - Yahoo Finance
Finanzdaten der Humacyte Inc-Aktie (HUMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):